Tofacitinib
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Tofacitinib: From Autoimmune Inflammatory Disease to Plasma Cell Myeloma
One-Sentence Summary
Tofacitinib is a JAK1/JAK3 inhibitor commonly used for autoimmune inflammatory conditions such as rheumatoid arthritis. Among ten TxGNN-predicted indications in this Evidence Pack, Plasma Cell Myeloma is the only candidate supported by actual literature (rather than pure model score), based on the IL-6/JAK/STAT3 signaling axis in the bone marrow microenvironment — but the evidence base is still early-stage, with 3 publications, no clinical trials, and mixed directionality (therapeutic potential vs. epidemiological risk signal).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this Evidence Pack (regulatory/MOA data gap). Tofacitinib is generally known as a JAK1/JAK3 inhibitor indicated for autoimmune inflammatory diseases (e.g., rheumatoid arthritis) |
| Predicted New Indication | Plasma Cell Myeloma |
| TxGNN Prediction Score | 96.09% (rank #4 by score among candidates; the top-ranked candidate was excluded — see note below) |
| Evidence Level | L3 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Note on candidate selection: The TxGNN model’s #1-ranked candidate by raw score, colobomatous microphthalmia-rhizomelic dysplasia syndrome, is explicitly flagged in the Evidence Pack’s own rationale as knowledge-graph embedding noise with no biological plausibility (a rare congenital skeletal/ocular developmental syndrome unrelated to JAK-STAT signaling). Ranks #1–3 and #6–10 are similarly disease groups with no mechanistic link, no clinical trials, and no literature. Plasma Cell Myeloma (rank #4) is the only candidate reaching decision stage S1 with real literature support, so it is used as the focus of this report.
Why is This Prediction Reasonable?
Detailed mechanism of action data for tofacitinib is not available in this Evidence Pack (data gap DG002). Based on generally known information, tofacitinib is a JAK1/JAK3 inhibitor approved for autoimmune inflammatory diseases; its efficacy in conditions such as rheumatoid arthritis is well established through blockade of cytokine-driven JAK-STAT signaling in immune cells.
The IL-6/JAK/STAT3 axis is also a central survival and proliferation pathway for multiple myeloma cells within the bone marrow microenvironment: bone marrow stromal cells secrete IL-6, which activates JAK1/JAK2/JAK3-STAT3 signaling in malignant plasma cells. Because tofacitinib blocks this same pathway, there is mechanistic plausibility for an anti-myeloma effect, and this is directly supported by a preclinical drug-repurposing study (PMID 29622655) showing tofacitinib reverses bone-marrow-microenvironment-induced growth-promoting effects on myeloma cells.
However, two pharmacoepidemiology studies in this Evidence Pack (PMID 38071595, PMID 39819734) examine DMARD/JAK-inhibitor exposure in relation to multiple myeloma risk rather than treatment benefit, meaning the directionality of the drug-disease relationship (protective vs. risk-associated) is not yet resolved. This is why the evidence level is capped at L3 (observational-level evidence) rather than higher.
Clinical Trial Evidence
Currently no related clinical trials registered for tofacitinib in plasma cell myeloma.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29622655 | 2018 | Preclinical (mechanistic) | Haematologica | Tofacitinib, identified via a prior repurposing screen, reversed the growth-promoting effects of bone marrow mesenchymal stromal cells on myeloma cells by blocking JAK/STAT signaling |
| 38071595 | 2024 | Cohort/registry association study | J Eur Acad Dermatol Venereol | FDA FAERS pharmacovigilance study found associations between multiple myeloma, immunosuppressive/immunomodulatory drugs, and sebaceous carcinoma reporting — informative on immune context but not a treatment-efficacy study |
| 39819734 | 2025 | Cohort (pharmacoepidemiology) | BMC Rheumatology | US Veterans cohort study assessing whether biologic/targeted synthetic DMARD use (including JAK inhibitors) in rheumatoid arthritis patients affects subsequent multiple myeloma incidence |
EU Market Information
Currently no EU marketing authorization is on record for tofacitinib in this Evidence Pack (market status: Not Marketed, 0 authorizations, no license entries available).
Other TxGNN Candidates (Screened Out)
For transparency, the remaining candidates in this Evidence Pack were assessed and deprioritized:
| Disease | TxGNN Score | Evidence Level | Reason for Deprioritization |
|---|---|---|---|
| Colobomatous microphthalmia-rhizomelic dysplasia syndrome | 98.96% | L5 | Congenital structural syndrome, no JAK-STAT relevance — flagged as model noise |
| Brachydactyly-syndactyly syndrome | 98.88% | L5 | Congenital limb syndrome, no mechanistic link, no evidence |
| Indolent plasma cell myeloma | 96.66% | L5 | Extrapolated from plasma cell myeloma signal, but no independent trials or literature |
| Myeloid leukemia | 95.43% | L4 | Mixed/contradictory signal — preclinical synergy with imatinib in CML vs. a case report of CML onset during tofacitinib therapy; no prospective evidence |
| Ganglioneuroblastoma | 79.55% | L5 | Pediatric neuroblastic tumor, no mechanistic or clinical support |
| Macrothrombocytopenia with mitral valve insufficiency | 76.17% | L5 | Rare genetic platelet disorder, unrelated to JAK-STAT immunomodulation |
| Hereditary thrombocytopenia with normal platelets | 75.76% | L5 | Genetic platelet disorder, not inflammation/immune-driven |
| Vertebral anomalies with variable endocrine and T-cell dysfunction | 75.34% | L5 | Congenital T-cell developmental defect — tofacitinib would suppress, not restore, T-cell function (mechanism runs opposite to therapeutic need) |
| Retroperitoneal neoplasm | 75.26% | L5 | Heterogeneous tumor group, no JAK-STAT dependency evidence |
Safety Considerations
Please refer to the SmPC for safety information. Note that TFDA label warnings/contraindications for tofacitinib are currently a blocking data gap (DG001) in this Evidence Pack, and must be resolved before any safety-stage (S1+) evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: Plasma cell myeloma is the only TxGNN-predicted indication with genuine mechanistic and literature support (L3, one supportive preclinical repurposing study), but the two pharmacoepidemiology studies raise an unresolved question of whether JAK inhibition is protective or a risk factor for myeloma. Combined with the absence of any clinical trials and a blocking gap in formal safety/label data, the evidence is not yet sufficient to proceed.
To proceed, the following is needed:
- TFDA/EMA product label warnings and contraindications (DG001, blocking)
- Documented mechanism of action (MOA) confirmation (DG002)
- Resolution of the directionality question (anti-myeloma therapeutic effect vs. myeloma risk association) through dedicated mechanistic or prospective clinical studies
- Confirmation of current EU marketing authorization status, since this Evidence Pack shows the drug as not marketed
- Initiation of an early-phase clinical trial or structured case-series review if preclinical rationale is prioritized further
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.